Metis Partners was appointed by PEM to sell the IP assets of Enigma Diagnostics from bankruptcy.
Enigma Diagnostics was established in 2004 to commercialize innovative molecular diagnostic technology, which was based on technology that had been initially developed at the UK’s Ministry of Defence’s Science Technology Laboratory.
The technology was developed to provide easy and fast molecular diagnostics through its internationally-patented Enigma Minilab device, using Polymerase Chain Reaction technology. This test platform was designed to be used in clinical laboratories or for diagnostics in hospitals, clinics, and pharmacies.
IP Assets Sold
- Patent portfolio
- Registered designs
- Registered & unregistered trademarks
- Key organizational knowledge
- Website content & domains
Highlight of this IP Sale
Metis Partners ran a highly competitive global sales process which resulted in multiple offers. Interestingly, the ultimate acquirer, Rapid Diagnostics, utilized the technology to develop a real-time PCR point-of-care COVID-19 detection test which can return a diagnostic result in around 40 minutes.